Literature DB >> 12796192

Extra-fine particles improve lung delivery of inhaled steroids in infants: a study in an upper airway model.

Hettie M Janssens1, Johan C De Jongste, Wim C J Hop, Harm A W M Tiddens.   

Abstract

BACKGROUND: The particles of a new hydrofluoroalkane-134a (HFA)-beclomethasone dipropionate (BDP) metered-dose inhaler (Qvar; 3M Pharmaceuticals; St. Paul, MN) are considerably smaller than those of chlorofluorocarbon (CFC)-BDP. This may improve lung deposition in infants who inhale nasally and have irregular breathing patterns and small airways. AIM: To compare the dose delivered to the lungs of HFA-BDP and CFC-BDP at different breathing patterns using an upper airway model of an infant.
METHODS: An anatomically correct upper airway model of a 9-month-old child with an open nasal airway was connected to an impactor and breathing simulator. HFA-BDP, 100 microg, and CFC-BDP, 100 micro g, were delivered to the model through a detergent-coated, small-volume spacer. The total dose leaving the model (lung dose), its particle size distribution, and median mass aerodynamic diameter (MMAD) were assessed during simulated tidal breathing with tidal volumes (VTs) of 50 mL, 100 mL, and 200 mL, and 30 breaths/min. Dose was expressed as percentage of nominal dose.
RESULTS: Lung doses for HFA-BDP were 25.4%, 26.5%, and 30.7% compared with 6.8%, 4.8%, and 2.1% for CFC-BDP at VTs of 50 mL, 100 mL, and 200 mL, respectively. The dose of particles < 2.1 microm to the lung for HFA-BDP was 23 to 28% compared with 0.6 to 0.8% for CFC-BDP. The lung dose of CFC-BDP mainly consisted of particles between 2.1 microm and 4.7 microm. MMAD for HFA-BDP was 1.2 microm, and 2.6 to 3.3 microm for CFC-BDP depending on VT. The lung dose for CFC-BDP decreased significantly with increasing VT. HFA-BDP lung dose did not alter significantly with VT.
CONCLUSIONS: In this infant model study, the use of HFA-BDP with a high dose of particles < 2.1 microm improves the dose delivered to the lungs substantially. Furthermore, the large proportion of extra-fine particles in HFA-BDP results in lung doses less dependent on breathing pattern compared with CFC-BDP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796192     DOI: 10.1378/chest.123.6.2083

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

1.  The interaction between the oropharyngeal geometry and aerosols via pressurised metered dose inhalers.

Authors:  T Ehtezazi; I Saleem; I Shrubb; D R Allanson; I D Jenkinson; C O'Callaghan
Journal:  Pharm Res       Date:  2009-11-10       Impact factor: 4.200

2.  Inhaled hydrofluoalkane-beclomethasone dipropionate in bronchopulmonary dysplasia. A double-blind, randomized, controlled pilot study.

Authors:  A Kugelman; M Peniakov; S Zangen; Y Shiff; A Riskin; A Iofe; I Shoris; D Bader; S Arnon
Journal:  J Perinatol       Date:  2016-10-13       Impact factor: 2.521

3.  Urinary pharmacokinetic methodology to determine the relative lung bioavailability of inhaled beclometasone dipropionate.

Authors:  Amira S A Said; Lindsay P Harding; Henry Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

4.  Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a.

Authors:  Thomas E Tarara; Michael S Hartman; Howard Gill; Alan A Kennedy; Jeffry G Weers
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

Review 5.  Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices.

Authors:  Eric Derom; Romain A Pauwels
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Respiratory lumenal change of the pharynx and trachea in normal subjects and COPD patients: assessment by cine-MRI.

Authors:  Claus Peter Heussel; Sebastian Ley; Alexander Biedermann; Anja Rist; Klaus Kurt Gast; Wolfgang G Schreiber; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2004-10-26       Impact factor: 5.315

Review 7.  Use of inhaler devices in pediatric asthma.

Authors:  Fernando Maria De Benedictis; David Selvaggio
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

8.  The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial.

Authors:  Marieke J J Ermers; Maroeska M Rovers; Job B van Woensel; Jan L L Kimpen; Louis J Bont
Journal:  BMJ       Date:  2009-03-31

9.  A whole lung in silico model to estimate age dependent particle dosimetry.

Authors:  Kamran Poorbahrami; Irene E Vignon-Clementel; Shawn C Shadden; Jessica M Oakes
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

10.  Asian dust storm elevates children's respiratory health risks: a spatiotemporal analysis of children's clinic visits across Taipei (Taiwan).

Authors:  Hwa-Lung Yu; Lung-Chang Chien; Chiang-Hsing Yang
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.